Aclarion

Track record is mixed. Positive: decisive 2025–2026 financings bolstered liquidity and eliminated interest expense; current cash supports key catalysts. Concern: heavy past dilution, three reverse splits in 2024–2025 (1:16, 1:335, 1:27), and a $2.5 million repurchase despite negative FCF and early‑stage commercialization.

The March 2026 one‑year stockholder rights plan and June 2026 rejection of Echo Lake Capital’s unsolicited $4.00 per share proposal signal a protective stance but also raise questions on opportunity cost and alignment. We prefer reinvestment in trials, market access, and product over buybacks until the business model is validated.